期刊文献+

大肠癌生物治疗临床应用研究进展 被引量:7

Research progress on colorectal cancer biology treatment in clinical application
在线阅读 下载PDF
导出
摘要 近年来,随着生物技术的快速发展,针对大肠癌所进行的基因治疗、免疫治疗等生物治疗研究日趋增多,在临床上取得一定的成果,成为继手术、放疗、化疗后的第四种治疗手段,越来越受到人们的广泛重视。本文对大肠癌的分子靶向治疗、基因治疗、细胞免疫治疗临床应用研究进展进行综述。 In recent years, with the rapid development of biotechnology, the research in colorectal cancer gene thera- py, immune therapy such as biological therapy. Become the fourth treatments after the surgery, radiotherapy and chem- otherapy treatments,more and more get the wide attention of people. In this paper, the molecular target therapy for colorectal cancer, gene therapy, cell immunotherapy with be summarized.
出处 《现代肿瘤医学》 CAS 2014年第7期1707-1711,共5页 Journal of Modern Oncology
关键词 大肠癌 生物治疗 临床应用 colorectal cancer biological treatment clinical application
  • 相关文献

参考文献40

  • 1Zuckerman DS,Clark JW.Systemic therapy for metastatic colorectal cancer:current questions[J].Cancer,2008,12(9):1879-1891.
  • 2Sorokin P.New agents and future directions in biotherapy [J].Clin J Oncol Nurs,2002,6(1):19-24.
  • 3Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis[J].Eur J Cancer,2001,37(1):S9-S15.
  • 4Goldstein NS,Armin M.Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma:implications for a standardized scoring system[J].Cancer,2001,92:1331-1346.
  • 5宫媛,吴本俨.循证医学评价结肠癌辅助化疗药物及新进展[J].中国新药杂志,2007,16(10):757-761. 被引量:7
  • 6Alberts SR.Effect of oxaliplatin,fluorouracil,and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer:a randomized trial[J].JAMA,2012,307(13):1383-1393.
  • 7Bentley TG,Broder MS,Das L,et al.Targeted therapies for metastatic colorectal cancer(mCRC):A systematic review of cost-effectiveness(CE)[J].J Clin Oncol,2012,30(4 suppl):583.
  • 8Siena S,Tabernero J,Cunningham D,et al.Randomized phase III study of panitumumab(pmab)with FOLFOX4 compared to FOLFOX4 alone as first-line treatment(tx)for metastatic colorectal cancer(mCRC):PRIME trial analysis by epidermal growth factor receptor(EGFR)tumor staining [J].J Clin Oncol,2010,28(Suppl 15s):3566.
  • 9Van Cutsem E,Peeters M,Siena S,et al.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-re-fractory metastatic colorectal cancer [J].J Clin Oncol,2007,25(13):1658-1664.
  • 10Tejpar S,Peeters M,Humblet Y,et al.Relationship of efficacy with KRAS status(wild type versus mutant)in patients with irinotecan-refractory metastatic colorectal cancer(mCRC),treated with irinotecan(q2w)and escalating doses of cetuximab(q1w):The EVEREST experience(preliminary data)[J].J Clin Oncol,2008,20(Suppl):4001.

二级参考文献134

共引文献161

同被引文献87

引证文献7

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部